eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

2/2018
vol. 43
 
Share:
Share:
more
 
 
abstract:
Review paper

The role of pharmacogenetics of cytochrome P450s in phenytoin-induced DRESS syndrome

Ümit Yaşar

(Centr Eur Immunol 2018; 43 (2): 220-221)
Online publish date: 2018/06/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Anil et al. (2017) report a patient who presented with drug rash with eosinophilia and systemic symptom (DRESS) syndrome. It may be induced by various drugs. In the mentioned report DRESS syndrome has been attributed to phenytoin use.

CYP2C9 is a genetically polymorphic enzyme, and decreased metabolism of many drugs has been reported in the subjects carrying variants of rs1799853 and rs1057910, which were designated as CYP2C9*2 and *3. rs3758581, the variant investigated by Anil et al., is a genetic variant of CYP2C19 (not that of CYP2C9, as stated and discussed in the report). CYP2C19 is also a highly genetically polymorphic enzyme, and rs3758581 may be present in 40 different haplotypes of CYP2C19 including *2 and *17 (for detailed information: www.pharmvar.org/gene/CYP2C19). Detection of rs3758581 is not sufficient because the patient presented by Anil H et al. may have CYP2C19*2, CYP2C19*17, or any other variant due to the co-appearance of other possible genetic variations. It is of importance to perform the correct genetic analysis because CYP2C19*2 is associated with low enzyme activity but CYP2C19*17 is associated with increased enzyme activity.

CYP2C9 is a major enzyme responsible for the metabolism of phenytoin. CYP2C9*2 (rs1799853) and *3 (rs1057910) should be considered in a Caucasian subject. CYP2C19 (especially *2 and *17) and ABCB1 polymorphisms may also be considered for the evaluation of the patient. Additionally, serum phenytoin levels would be helpful to understand the contribution of genetic polymorphisms on the pharmacokinetics of phenytoin in the patients presenting side effects like DRESS syndrome.
keywords:

phenytoin, genetic polymorphism, DRESS syndrome, cytochrome P450

references:
Anil H, Harmanci K, Tekin RT, Kocak A (2017): Presence of a single nucleotide polymorphism (RS3758581) in a boy with DRESS syndrome. Cent Eur J Immunol 42: 409-411.
Erdem SB, Nacaroglu HT, Bag O, et al. (2015): DRESS syndrome associated with type 2 diabetes in a child. Cent Eur
J Immunol 40: 493-496.
Sandberg M, Yasar U, Stromberg P, et al. (2002): Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 54: 423-429.
Babaoglu M, Yasar U, Sandberg M, et al. (2004): CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 60: 337-342.
Yampayon K, Sukasem C, Limwongse C, et al. (2017): Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharmacol 73: 855-865.
Gumus E, Karaca O, Babaoglu MO, et al. (2012): Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 68: 629-636.
Brandolese R, Scordo MG, Spina E, et al. (2001): Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 70: 391-394.
Shaheen U, Prasad DK, Sharma V, et al. (2014): Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. Epilepsy Res 108: 251-256.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe